9/16/2021 7:56:48 AM
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy
9/14/2021 7:41:52 AM
Axsome Therapeutics: FDA Accepts AXS-07 NDA For Acute Treatment Of Migraine
8/23/2021 6:22:51 AM
FDA Misses PDUFA Deadline For Axsome's MDD Drug, No Additional Data Sought
6/15/2021 7:16:03 AM
Axsome Therapeutics Plans To Submit NDA For Management Of Fibromyalgia In Q4 Of 2022
4/26/2021 6:06:23 AM
Axsome Therapeutics: FDA Accepts NDA Filing For AXS-05 For Major Depressive Disorder
12/31/2020 6:41:48 AM
Axsome Therapeutics Begins ACCORD Phase 3 Trial Of AXS-05 In Alzheimer’s Disease Agitation
12/31/2020 6:06:22 AM
Axsome Therapeutics Announces Positive Results From Phase 3 MOVEMENT Trial Of AXS-07 In Acute Treatment Of Migraine
12/8/2020 6:02:59 AM
Axsome Therapeutics Reports Positive Results From COMET-SI Trial Of AXS-05 In Patients With Major Depressive Disorder
12/2/2020 6:10:10 AM
Axsome Therapeutics Announces Positive Results From Open-label Phase 2 COMET-TRD Trial Of AXS-05
12/1/2020 6:12:49 AM
Axsome Therapeutics Announces Positive Results From Phase 3 COMET Long-Term Trial And COMET-AU Trial Of AXS-05
9/24/2020 6:10:17 AM
Axsome: AXS-07 Demonstrated Faster, More Durable Relief Of Migraine Pain As Compared To Rizatriptan
9/21/2020 7:07:53 AM
Axsome Therapeutics Says Development Plan For AXS-12 For Treatment Of Narcolepsy Has Been Expedited
9/14/2020 6:03:13 AM
Axsome Therapeutics Presents New Data From GEMINI Phase 3 Trial With AXS-05